{"id":13852,"date":"2025-10-14T11:46:41","date_gmt":"2025-10-14T04:46:41","guid":{"rendered":"https:\/\/nhathuocngocanh.com\/bp\/?p=13852"},"modified":"2025-10-14T11:46:41","modified_gmt":"2025-10-14T04:46:41","slug":"erythromycin-ethyl-succinate","status":"publish","type":"post","link":"https:\/\/nhathuocngocanh.com\/bp\/erythromycin-ethyl-succinate\/","title":{"rendered":"Erythromycin Ethyl Succinate"},"content":{"rendered":"<p><em>(Erythromycin Ethylsuccinate, Ph. Eur. monograph 0274)<\/em><\/p>\n<p><strong>Action and use<\/strong><\/p>\n<p>Macrolide antibacterial.<\/p>\n<p><strong>Preparations<\/strong><\/p>\n<p>Erythromycin Ethyl Succinate Oral Suspension<\/p>\n<p>Erythromycin Ethyl Succinate Tablets<\/p>\n<h2>DEFINITION<\/h2>\n<p>Mixture of the ethylsuccinate esters of erythromycin.<\/p>\n<p>Main component (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-4-[(2,6-dideoxy-3-C-methyl-3-O-methyl-\u03b1-L-ribo- hexopyranosyl)oxy]-14-ethyl-7,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-6-[[3,4,6-trideoxy-3-(dimethylamino)-2-O-(4-ethoxy-4-oxobutanoyl)-\u03b2-D-xylo-hexopyranosyl]oxy]oxacyclotetradecane-2,10-dione (erythromycin A 2\u2032\u2032-(ethyl succinate)).<\/p>\n<p>Semi-synthetic product derived from a fermentation product obtained using a strain of Streptomyces erythreus.<\/p>\n<h3>Content<\/h3>\n<p>\u2014 sum of erythromycins A, B and C expressed as ethylsuccinates: 93.0 per cent to 102.0 per cent (anhydrous substance);<\/p>\n<p>\u2014 erythromycin B ethylsuccinate: maximum 5.0 per cent (anhydrous substance);<\/p>\n<p>\u2014 erythromycin C ethylsuccinate: maximum 5.0 per cent (anhydrous substance).<\/p>\n<h2>CHARACTERS<\/h2>\n<h3>Appearance<\/h3>\n<p>White or almost white, crystalline powder, hygroscopic.<\/p>\n<h3>Solubility<\/h3>\n<p>Practically insoluble in water, freely soluble in acetone, in anhydrous ethanol and in methanol.<\/p>\n<h2>IDENTIFICATION<\/h2>\n<p>Infrared absorption spectrophotometry (2.2.24).<\/p>\n<p>Comparison erythromycin ethylsuccinate CRS.<\/p>\n<h2>TESTS<\/h2>\n<h3>Related substances<\/h3>\n<p>Liquid chromatography (2.2.29).<\/p>\n<p>Hydrolysis solution A 20 g\/L solution of dipotassium hydrogen phosphate R adjusted to pH 8.0 with phosphoric acid R.<\/p>\n<p>Test solution: Dissolve 0.115 g of the substance to be examined in 25 mL of methanol R. Add 20 mL of the hydrolysis solution, mix and allow to stand at room temperature for at least 12 h. Dilute to 50.0 mL with the hydrolysis solution.<\/p>\n<p>Reference solution (a): Dissolve 40.0 mg of erythromycin A CRS in 10 mL of methanol R and dilute to 20.0 mL with the hydrolysis solution.<\/p>\n<p>Reference solution (b): Dissolve 10.0 mg of erythromycin B CRS and 10.0 mg of erythromycin C CRS in 50 mL of methanol R. Add 5.0 mL of reference solution (a) and dilute to 100.0 mL with the hydrolysis solution.<\/p>\n<p>Reference solution (c): Dissolve 2 mg of N-demethylerythromycin A CRS in 20 mL of reference solution (b).<\/p>\n<p>Reference solution (d): Dilute 3.0 mL of reference solution (a) to 100.0 mL with a mixture of equal volumes of methanol R and the hydrolysis solution.<\/p>\n<p>Reference solution (e): Dissolve 40 mg of erythromycin A CRS, previously heated at 130 \u00b0C for 3 h, in 10 mL of methanol R and dilute to 20 mL with the hydrolysis solution.<\/p>\n<p>Column:<\/p>\n<p>\u2014 size: l = 0.25 m, \u00d8 = 4.6 mm;<\/p>\n<p>\u2014 stationary phase: styrene-divinylbenzene copolymer R (8 \u03bcm) with a pore size of 100 nm;<\/p>\n<p>\u2014 temperature: 70 \u00b0C using a water-bath for the column and at least one-third of the tubing preceding the column.<\/p>\n<p>Mobile phase: To 50 mL of a 35 g\/L solution of dipotassium hydrogen phosphate R adjusted to pH 8.0 with dilute phosphoric acid R, add 400 mL of water for chromatography R, 165 mL of 2-methyl-2-propanol R and 30 mL of acetonitrile R1, and dilute to 1000 mL with water for chromatography R.<\/p>\n<p>Flow rate: 2.0 mL\/min.<\/p>\n<p>Detection: Spectrophotometer at 215 nm.<\/p>\n<p>Injection: 200 \u03bcL of the test solution and reference solutions (a), (c), (d) and (e).<\/p>\n<p>Run time: 5 times the retention time of erythromycin A; begin integration after the hydrolysis peak.<\/p>\n<p>Relative retention: With reference to erythromycin A (retention time = about 15 min): hydrolysis peak = less than 0.3; impurity B = about 0.45; erythromycin C = about 0.5; impurity C = about 0.9; impurity G = about 1.3; impurity D = about 1.4; impurity F = about 1.5; erythromycin B = about 1.8; impurity E = about 4.3.<\/p>\n<p>System suitability: Reference solution (c):<\/p>\n<p>\u2014 resolution: minimum 0.8 between the peaks due to impurity B and erythromycin C and minimum 5.5 between the peaks due to impurity B and erythromycin A.<\/p>\n<p>Limits:<\/p>\n<p>\u2014 correction factors: for the calculation of contents, multiply the peak areas of the following impurities by the corresponding correction factor: impurity E = 0.09; impurity F = 0.15; impurity G = 0.14; use the chromatogram obtained with reference solution (e) to identify the peaks due to impurities E and F;<\/p>\n<p>\u2014 any impurity: not more than the area of the principal peak in the chromatogram obtained with reference solution (d) (3.0 per cent);<\/p>\n<p>\u2014 total: not more than 1.67 times the area of the principal peak in the chromatogram obtained with reference solution (d) (5.0 per cent);<\/p>\n<p>\u2014 disregard limit: 0.02 times the area of the principal peak in the chromatogram obtained with reference solution (d) (0.06 per cent).<\/p>\n<h3>Free erythromycin<\/h3>\n<p>Liquid chromatography (2.2.29).<\/p>\n<p>Test solution: Dissolve 0.250 g of the substance to be examined in acetonitrile R and dilute to 50.0 mL with the same solvent.<\/p>\n<p>Reference solution: Dissolve 75.0 mg of erythromycin A CRS in acetonitrile R and dilute to 50.0 mL with the same solvent.<\/p>\n<p>Dilute 5.0 mL of the solution to 25.0 mL with acetonitrile R.<\/p>\n<p>Column:<\/p>\n<p>\u2014 size: l = 0.25 m, \u00d8 = 4.6 mm;<\/p>\n<p>\u2014 stationary phase: octylsilyl silica gel for chromatography R (5 \u03bcm);<\/p>\n<p>\u2014 temperature: 30 \u00b0C.<\/p>\n<p>Mobile phase: Mix 35 volumes of acetonitrile R1 and 65 volumes of a solution containing 3.4 g\/L of potassium dihydrogen phosphate R and 2.0 g\/L of triethylamine R, previously adjusted to pH 3.0 with dilute phosphoric acid R.<\/p>\n<p>Flow rate: 1 mL\/min.<\/p>\n<p>Detection: Spectrophotometer at 195 nm.<\/p>\n<p>Injection: 20 \u03bcL.<\/p>\n<p>Run time: Twice the retention time of erythromycin A (retention time = about 8 min) for the reference solution; twice the retention time of erythromycin ethylsuccinate (retention time = about 24 min) for the test solution.<\/p>\n<p>Limit:<\/p>\n<p>\u2014 free erythromycin: not more than the area of the principal peak in the chromatogram obtained with the reference solution (6.0 per cent).<\/p>\n<h3>Water (2.5.12)<\/h3>\n<p>Maximum 3.0 per cent, determined on 0.300 g.<\/p>\n<p>Use a 100 g\/L solution of imidazole R in anhydrous methanol R as the solvent.<\/p>\n<h3>Sulfated ash (2.4.14)<\/h3>\n<p>Maximum 0.3 per cent, determined on 1.0 g.<\/p>\n<h2>ASSAY<\/h2>\n<p>Liquid chromatography (2.2.29). Prepare the solutions immediately before use (apart from the test solution).<\/p>\n<p>Solution A (hydrolysis solution). Dissolve 11.5 g of dipotassium hydrogen phosphate R in 900 mL of water R, adjust to pH 8.0 with dilute phosphoric acid R and dilute to 1000 mL with water R.<\/p>\n<p>Solvent mixture methanol R, solution A (40:60 V\/V).<\/p>\n<p>Test solution: Dissolve 11.5 mg of the substance to be examined in 2.5 mL of methanol R. Add 2 mL of solution A, mix and allow to stand at room temperature for at least 12 h. Dilute to 5.0 mL with solution A.<\/p>\n<p>Reference solution (a): Dissolve 40.0 mg of erythromycin A CRS in 10.0 mL of methanol R and dilute to 20.0 mL with solution A.<\/p>\n<p>Reference solution (b): Dissolve 10.0 mg of erythromycin B CRS and 10.0 mg of erythromycin C CRS in 50.0 mL of methanol R and dilute to 100.0 mL with solution A.<\/p>\n<p>Column:<\/p>\n<p>\u2014 size: l = 0.25 m, \u00d8 = 4.6 mm;<\/p>\n<p>\u2014 stationary phase: end-capped polar-embedded octadecylsilyl amorphous organosilica polymer R (3.5 \u03bcm);<\/p>\n<p>\u2014 temperature: 65 \u00b0C; preheating the mobile phase may be required, for instance by extending the inlet tubing in the oven to 30 cm.<\/p>\n<p>Mobile phase:<\/p>\n<p>\u2014 mobile phase A: phosphate buffer solution pH 7.0 R7, acetonitrile R1, water for chromatography R (5:35:60 V\/V\/V);<\/p>\n<p>\u2014 mobile phase B: phosphate buffer solution pH 7.0 R7, water for chromatography R, acetonitrile R1 (5:45:50 V\/V\/V);<\/p>\n<table style=\"border-collapse: collapse; width: 100%; height: 108px;\">\n<tbody>\n<tr style=\"height: 45px;\">\n<td style=\"width: 33.3333%; height: 45px; text-align: center;\"><strong>Time<\/strong><\/p>\n<p><strong>(min)<\/strong><\/td>\n<td style=\"width: 33.3333%; height: 45px; text-align: center;\"><strong>Mobile phase A<\/strong><\/p>\n<p><strong>(per cent V\/V)<\/strong><\/td>\n<td style=\"width: 33.3333%; height: 45px; text-align: center;\"><strong>Mobile phase B<\/strong><\/p>\n<p><strong>(per cent V\/V)<\/strong><\/td>\n<\/tr>\n<tr style=\"height: 21px;\">\n<td style=\"width: 33.3333%; height: 21px; text-align: center;\">0 &#8211; t<sub>R<\/sub><\/td>\n<td style=\"width: 33.3333%; height: 21px; text-align: center;\">100<\/td>\n<td style=\"width: 33.3333%; height: 21px; text-align: center;\">0<\/td>\n<\/tr>\n<tr style=\"height: 21px;\">\n<td style=\"width: 33.3333%; height: 21px; text-align: center;\">t<sub>R<\/sub> &#8211; (t<sub>R<\/sub> + 2)<\/td>\n<td style=\"width: 33.3333%; height: 21px; text-align: center;\">100 \u2192 0<\/td>\n<td style=\"width: 33.3333%; height: 21px; text-align: center;\">0 \u2192 100<\/td>\n<\/tr>\n<tr style=\"height: 21px;\">\n<td style=\"width: 33.3333%; height: 21px; text-align: center;\">(t<sub>R<\/sub> + 2) &#8211; (t<sub>R<\/sub> + 15)<\/td>\n<td style=\"width: 33.3333%; height: 21px; text-align: center;\">0<\/td>\n<td style=\"width: 33.3333%; height: 21px; text-align: center;\">100<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>t<sub>R<\/sub> = retention time of erythromycin B, determined by injecting 20 \u03bcL of reference solution (b) and eluting with mobile phase A<\/p>\n<p>Flow rate: 1.0 mL\/min.<\/p>\n<p>Detection: Spectrophotometer at 210 nm.<\/p>\n<p>Autosampler: Set at 4 \u00b0C.<\/p>\n<p>Injection: 200 \u03bcL.<\/p>\n<p>System suitability: Reference solution (a):<\/p>\n<p>\u2014 symmetry factor: maximum 2.5 for the peak due to erythromycin A;<\/p>\n<p>\u2014 repeatability: maximum relative standard deviation of 1.0 per cent determined on 6 injections.<\/p>\n<p>Calculate the percentage content of erythromycin A (C<sub>37<\/sub>H<sub>67<\/sub>NO<sub>13<\/sub>) using the chromatogram obtained with reference solution (a). Calculate the percentage contents of erythromycin B (C<sub>37<\/sub>H<sub>67<\/sub>NO<sub>12<\/sub>) and erythromycin C (C<sub>36<\/sub>H<sub>65<\/sub>NO<sub>13<\/sub>) using the chromatogram obtained with reference solution (b).<\/p>\n<p>Express the results as erythromycin A ethylsuccinate, erythromycin B ethylsuccinate and erythromycin C ethylsuccinate by multiplying the percentage content of erythromycin A by 1.1744, the percentage content of erythromycin B by 1.1783 and percentage content of erythromycin C by 1.1777.<\/p>\n<p>For the calculation of content of erythromycin ethylsuccinate, use the sum of erythromycins A, B and C expressed as ethylsuccinates as described above.<\/p>\n<h2>STORAGE<\/h2>\n<p>In an airtight container, protected from light.<\/p>\n<h2>IMPURITIES<\/h2>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-13873\" src=\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/2-176-300x163.jpg\" alt=\"Erythromycin Ethyl Succinate \" width=\"300\" height=\"163\" srcset=\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/2-176-300x163.jpg 300w, https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/2-176-1024x555.jpg 1024w, https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/2-176-768x416.jpg 768w, https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/2-176.jpg 1200w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/p>\n<p>A. (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-4-[(2,6-dideoxy-3-C-methyl-3-O-methyl-\u03b1-L-ribo-hexopyranosyl)oxy]-14-ethyl- 7,12,13-trihydroxy-3-(hydroxymethyl)-5,7,9,11,13-pentamethyl-6-[[3,4,6-trideoxy-3-(dimethylamino)-\u03b2-D-xylo-hexopyranosyl]oxy]oxacyclotetradecane-2,10-dione (erythromycin F),<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-13874\" src=\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/3-164-300x163.jpg\" alt=\"Erythromycin Ethyl Succinate \" width=\"300\" height=\"163\" srcset=\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/3-164-300x163.jpg 300w, https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/3-164-1024x555.jpg 1024w, https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/3-164-768x416.jpg 768w, https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/3-164.jpg 1200w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/p>\n<p>B. (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-4-[(2,6-dideoxy-3-C-methyl-3-O-methyl-\u03b1-L-ribo-hexopyranosyl)oxy]-14-ethyl-7,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-6-[[3,4,6-trideoxy-3-(methylamino)-\u03b2-D-xylo-hexopyranosyl]oxy]oxacyclotetradecane-2,10-dione (3\u2032\u2032-N-demethylerythromycin A),<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-13875\" src=\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/4-151-300x163.jpg\" alt=\"Erythromycin Ethyl Succinate \" width=\"300\" height=\"163\" srcset=\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/4-151-300x163.jpg 300w, https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/4-151-1024x555.jpg 1024w, https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/4-151-768x416.jpg 768w, https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/4-151.jpg 1200w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/p>\n<p>C. (2S,4aR,4\u2032R,5\u2032S,6\u2032S,7R,8S,9R,10R,12R,14R,15R,16S,16aS)-7-ethyl-5\u2032,8,9,14-tetrahydroxy-4\u2032-methoxy-4\u2032,6\u2032,8,10,12,14,16-heptamethyl-15-[[3,4,6-trideoxy-3-(dimethylamino)-\u03b2-D-xylo-hexopyranosyl]oxy]hexadecahydrospiro[5H,11H-1,3-dioxino[5,4-c]oxacyclotetradecin-2,2\u2032-pyrane]-5,11-dione (erythromycin E),<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-13876\" src=\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/5-120-300x163.jpg\" alt=\"Erythromycin Ethyl Succinate \" width=\"300\" height=\"163\" srcset=\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/5-120-300x163.jpg 300w, https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/5-120-1024x555.jpg 1024w, https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/5-120-768x416.jpg 768w, https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/5-120.jpg 1200w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/p>\n<p>D. (1S,2R,3R,4S,5R,8R,9S,10S,11R,12R,14R)-9-[(2,6-dideoxy-3-C-methyl-3-O-methyl-\u03b1-L-ribo-hexopyranosyl)oxy]-5-ethyl-3-hydroxy-2,4,8,10,12,14-hexamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-\u03b2-D-xylo-hexopyranosyl]oxy]-6,15,16-trioxatricyclo[10.2.1.1 ]hexadecan-7-one (anhydroerythromycin A),<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-13877\" src=\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/6-95-300x163.jpg\" alt=\"Erythromycin Ethyl Succinate \" width=\"300\" height=\"163\" srcset=\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/6-95-300x163.jpg 300w, https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/6-95-1024x555.jpg 1024w, https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/6-95-768x416.jpg 768w, https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/6-95.jpg 1200w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/p>\n<p>E. (2R,3R,4S,5R,8R,9S,10S,11R,12R)-9-[(2,6-dideoxy-3-C-methyl-3-O-methyl-\u03b1-L-ribo-hexopyranosyl)oxy]-5-ethyl-3,4-dihydroxy-2,4,8,10,12,14-hexamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-\u03b2-D-xylo-hexopyranosyl]oxy]-6,15-dioxabicyclo[10.2.1]pentadec-1(14)-en-7-one (erythromycin A enol ether),<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-13878\" src=\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/7-78-300x163.jpg\" alt=\"Erythromycin Ethyl Succinate \" width=\"300\" height=\"163\" srcset=\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/7-78-300x163.jpg 300w, https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/7-78-1024x555.jpg 1024w, https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/7-78-768x416.jpg 768w, https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/7-78.jpg 1200w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/p>\n<p>F. (2R,3R,6R,7S,8S,9R,10R)-7-[(2,6-dideoxy-3-C-methyl-3-O-methyl-\u03b1-L-ribo-hexopyranosyl)oxy]-3-[(1R,2R)-1,2-dihydroxy-1-methylbutyl]-2,6,8,10,12-pentamethyl-9-[[3,4,6-trideoxy-3-(dimethylamino)-\u03b2-D-xylo-hexopyranosyl]oxy]-4,13-dioxabicyclo[8.2.1]tridec-1(12)-en-5-one (pseudoerythromycin A enol ether),<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-13879\" src=\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/8-56-300x163.jpg\" alt=\"Erythromycin Ethyl Succinate \" width=\"300\" height=\"163\" srcset=\"https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/8-56-300x163.jpg 300w, https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/8-56-1024x555.jpg 1024w, https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/8-56-768x416.jpg 768w, https:\/\/nhathuocngocanh.com\/bp\/wp-content\/uploads\/2025\/10\/8-56.jpg 1200w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/p>\n<p>G. (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-4-[(2,6-dideoxy-3-C-methyl-3-O-methyl-\u03b1-L-ribo-hexopyranosyl)oxy]-14-ethyl-7,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-6-[[3,4,6-trideoxy-3-[(4-ethoxy-4-oxobutanoyl)methylamino]-\u03b2-D-xylo-hexopyranosyl]oxy]oxacyclotetradecane-2,10-dione (3\u2032\u2032-N-demethyl-3\u2032\u2032-N-(ethoxysuccinyl)erythromycin A).<\/p>\n","protected":false},"excerpt":{"rendered":"<p>(Erythromycin Ethylsuccinate, Ph. Eur. monograph 0274) Action and use Macrolide antibacterial. Preparations Erythromycin Ethyl Succinate Oral Suspension Erythromycin Ethyl Succinate Tablets DEFINITION Mixture of the ethylsuccinate esters of erythromycin. Main component (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-4-[(2,6-dideoxy-3-C-methyl-3-O-methyl-\u03b1-L-ribo- hexopyranosyl)oxy]-14-ethyl-7,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-6-[[3,4,6-trideoxy-3-(dimethylamino)-2-O-(4-ethoxy-4-oxobutanoyl)-\u03b2-D-xylo-hexopyranosyl]oxy]oxacyclotetradecane-2,10-dione (erythromycin A 2\u2032\u2032-(ethyl succinate)). Semi-synthetic product derived from a fermentation product obtained using a strain of Streptomyces erythreus. Content \u2014 sum of&#8230;<\/p>\n","protected":false},"author":4,"featured_media":13872,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[174],"tags":[],"class_list":["post-13852","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medicinal-substances"],"acf":[],"_links":{"self":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/13852","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/comments?post=13852"}],"version-history":[{"count":2,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/13852\/revisions"}],"predecessor-version":[{"id":13891,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/13852\/revisions\/13891"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media\/13872"}],"wp:attachment":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media?parent=13852"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/categories?post=13852"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/tags?post=13852"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}